Harrison, C N, Mead, A J, Panchal, A, McMullin, M, Fox, S, Yap, C, Gbandi, E, Houlton, A, Alimam, S, Ewing, J, Wood, M, Chen, F, Coppell, J, Panoskaltsis, N, knapper, S, Ali, S, Hmblin, A, Scherber, R, Dueck, A C, Cross, N & Rubin, M 2017, ' Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomised trial ', Blood, vol. 130, no. 17, pp. 1889 . https://doi.org/10.1182/blood-2017-05-785790